FDA Authorizes Moderna, Janssen COVID-19 Booster Shots, Allows for Mix and Match
The decision comes following the results of two FDA advisory committee meetings.
The decision comes following the results of two FDA advisory committee meetings.
About half of patients with impaired seroconversion after the first dose of a COVID-19 vaccine still had low antibody levels after the second dose.
Having the tough conversations. NASEM offers recommendations for communicating with parents of young children about COVID-19 vaccines.
The panel reviewed safety and efficacy data from the phase 3 ENSEMBLE 2 study.
The Companies recently submitted data from a phase 2/3 trial that included 2268 pediatric participants.
Background materials for both meetings will be available to the public.
The survey asked about the likelihood of both child and parental vaccination, perceptions about the vaccines and the level of trust in various sources of information.
Participants 5 to 11 years of age received a 2-dose regimen of 10mcg administered 21 days apart.
Researchers sought to compare the risk for hospital and emergency department admission for the treatment of COVID-19 among patients infected with the Alpha variant vs those with the Delta variant.
A single 50µg dose of mRNA-1273 given as a booster increased neutralizing antibody titer responses above the phase 3 benchmark.